Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation

Locations

1 United States site

Age

< 17 Years

Study type

Observational

Gender

All

Compensation

Unknown

About the study

Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal
of this study is to determine what causes some children to have different drug concentrations
of fludarabine in their bodies and if drug levels are related to whether or not a child
experiences severe side-effects during their bone marrow transplant. The hypothesis is that
clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone
marrow transplant patients and that high levels may cause severe side-effects.

participation requirements

– Children 0-17 years of age

– Undergoing alloHCT for the treatment of malignant or nonmalignant disorder

– Receiving fludarabine-based preparative regimen

participation restrictions

– Any child 7-17 years of age unwilling to provide assent

– Parent or guardian unwilling to provide written consent

Locations

  • San Francisco, California, United States, University of California, San Francisco, 94143